Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
APPLE
Osimertinib Treatment on EGFR T790M Plasma Positive NSCLC Patients (APPLE)
- NCT02856893 ↗
- Completed
- European Organisation for Research and Treatment of Cancer - EORTC
- Focused
We haven't built an HCP commentary report on APPLE (osimertinib; osimertinib plus gefitinib in advanced EGFR-mutant NSCLC) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on APPLE so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR Mutant NSCLC Patients
- Phase
- Phase 2
- Status
- Completed
- Conditions
- NSCLC
- Interventions
- Osimertinib; Gefitinib
- Arms
- Osimertinib till progression · Experimental
- Gefitinib till + blood test/progression than Osimertinib · Experimental
- Gefitinib till progression than Osimertinib · Active comparator
- Enrollment
- 156
- Primary outcomes
- PFS Rate at 18 Months
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC with AstraZeneca
- Start
- Oct 10, 2017
- Primary completion
- Sep 20, 2022
- Results posted
- Yes
- Registry record
- NCT02856893 · updated Jun 2, 2026
Publications
linked from the registry- Remon J, Besse B, Aix SP, Callejo A, Al-Rabi K, Bernabe R, Greillier L, Majem M, Reguart N, Monnet I, Cousin S, Garrido P, Robinet G, Campelo RG, Madroszyk A, Mazieres J, Curcio H, Wasag B, Pretzenbacher Y, Grillet F, Dingemans AC, Dziadziuszko R. Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR-Mutant Non-Small-Cell Lung Cancer. J Clin Oncol. 2024 Apr 20;42(12):1350-1356. doi: 10.1200/JCO.23.01521. Epub 2024 Feb 7. PubMed 38324744